- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ted Kyle Discusses BMI as a Diagnostic Tool for Obesity
While body mass index is a good indicator for obesity, there are various other factors and clinical symptoms that need to be taken into account when diagnosing and treating a patient for obesity, explained Ted Kyle, RPh, MBA, principal at ConscienHealth.
While body mass index (BMI) can be a good indicator for obesity, there are various other factors and clinical symptoms that need to be taken into account when diagnosing and treating a patient for obesity, explained Ted Kyle, RPh, MBA, principal at ConscienHealth.
Transcript (slightly modified)
How much should BMI be taken into account when a patient is being diagnosed and treated for obesity?
BMI is one of these complicated things that is on the surface very simple. It’s a very useful screening tool, but when people think that BMI is the same thing as obesity, they’re mistaken. BMI is no more equivalent to obesity than a fever is to an infection. It’s a good sign. It’s a good easy sort of way to look for whether there might be a problem but obesity is really the excess of adipose tissue that accumulates and causes harm to health.
That excess visceral adipose tissue can be present at a fairly low BMI and actually cause quite a problem with health. It is more common at a high BMI, which is why BMI is used for a screening tool, but it’s only good as a screening tool. It’s not a diagnostic tool.
Can BMI be different among various ethnic groups?
Right, the cut points for different ethnic groups is different according to BMI. Again, BMI is just a rough indicator. What really matters is metabolically, how much metabolically active adipose tissue has accumulated around the visceral organs and how much is that harming health. There’s something called the Edmonton Obesity Staging System, which is a way of combining BMI with other clinical indicators to really give a good assessment of what someone’s disease state is.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
